ISIN | LU0432979614 |
---|---|
Valor Number | 10261626 |
Bloomberg Global ID | |
Fund Name | JPM Global Healthcare Fund A acc USD |
Fund Provider |
JPMorgan Asset Management (Switzerland) LLC
Dreikönigstrasse 37 Postfach 8022 Zürich Tel. +41 (0)44 206 86 00 |
Fund Provider | JPMorgan Asset Management (Switzerland) LLC |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Peculiarities |
Current Price * | 468.36 USD | 23.12.2024 |
---|---|---|
Previous Price * | 463.83 USD | 20.12.2024 |
52 Week High * | 557.48 USD | 03.09.2024 |
52 Week Low * | 463.83 USD | 20.12.2024 |
NAV * | 468.36 USD | 23.12.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 4,241,275,502 | |
Unit/Share Assets *** | 1,093,492,307 | |
Trading Information SIX |
YTD Performance | -2.43% |
29.12.2023 - 23.12.2024
29.12.2023 23.12.2024 |
---|---|---|
YTD Performance (in CHF) | +3.62% |
29.12.2023 - 23.12.2024
29.12.2023 23.12.2024 |
1 month | -5.45% |
25.11.2024 - 23.12.2024
25.11.2024 23.12.2024 |
3 months | -13.13% |
23.09.2024 - 23.12.2024
23.09.2024 23.12.2024 |
6 months | -9.57% |
24.06.2024 - 23.12.2024
24.06.2024 23.12.2024 |
1 year | -1.59% |
27.12.2023 - 23.12.2024
27.12.2023 23.12.2024 |
2 years | +0.34% |
23.12.2022 - 23.12.2024
23.12.2022 23.12.2024 |
3 years | -8.02% |
23.12.2021 - 23.12.2024
23.12.2021 23.12.2024 |
5 years | +24.78% |
23.12.2019 - 23.12.2024
23.12.2019 23.12.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
UnitedHealth Group Inc | 9.32% | |
---|---|---|
Eli Lilly and Co | 8.83% | |
AbbVie Inc | 5.78% | |
Novo Nordisk AS Class B | 5.25% | |
AstraZeneca PLC | 4.41% | |
Danaher Corp | 3.85% | |
Boston Scientific Corp | 3.77% | |
Stryker Corp | 3.58% | |
Bristol-Myers Squibb Co | 3.54% | |
Medtronic PLC | 3.40% | |
Last data update | 30.11.2024 |
TER *** | 1.70% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.72% |
SRRI ***
|
|
SRRI date *** | 30.11.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |